(2) Regulatory News: CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the world's most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, today announces that is has obtained a €1.4 million grant as a winner of the Ministry for Industry's "Industrial recovery plan Strategic sectors" call for projects. This non-dilutive financing will contribute to the "CAP 23" industrialization program that aims to size the production of the Aeson heart for its commercial phase, notably by: increasing CARMAT's production capacity on its Bois-d'Arcy industrial site; digitalizing this site; and